|
|
|
|
|
|
|
EXPERT LED JOURNAL CLUB DISCUSSIONS |
|
|
|
|
|
|
Treatment Effect of 177Lu-PSMA in Low-Volume mHSPC Patients, Journal Club
|
Zachary Klaassen, MD, MSc and Christopher Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen discuss a pilot study on Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients. The discussion begins with a look into the evolution of mHSPC treatment over the past five years, with an acknowledgment of the CHAARTED, STAMPEDE, and GETUG trials.
|
|
|
|
|
|
|
|
|
| Intermittent vs Continuous ADT for Patients A Review of the NCCN Guidelines |
| Zachary Klaassen, MD, MSc and Christopher Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen review the NCCN clinical practice guidelines on prostate cancer. This discussion is the third part of their discussion of androgen deprivation therapy (ADT). |
|
|
|
|
|
| The Role of 18F-Fluciclovine-PET/CT in Improving Cancer Control Compared With Conventional Imaging Alone for Salvage Postprostatectomy Radiotherapy, the EMPIRE-1 Trial, Journal Club
|
| Zachary Klaassen, MD, MSc and Christopher Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen discuss a publication entitled, “18F-Fluciclovine-PET/CT Imaging versus Conventional Imaging Alone to Guide Post-Prostatectomy Salvage Radiotherapy for Prostate Cancer, the EMPIRE-1 Study”. This Journal Club kicks off with a discussion about adjuvant radiotherapy in patients with prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Improved Survival for Men Treated With Enzalutamide Added to Testosterone Suppression Who Present With Distant Metastases Years After Diagnosis of mHSPC, Journal Club
|
| Zachary Klaassen, MD, MSc and Christopher Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen highlight a subset analysis from the ENZAMET trial looking at the impact of enzalutamide on survival outcomes in men whose cancer comes back years later after diagnosis.
|
|
|
|
|
|
|
|
|
|
|
|
